Seronegative spondyloarthropathies: To lump or split?

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 2, 2005, Pages

  Nash, P ^a   Mease, P J ^b   Braun, J ^c   Van Der Heijde, D ^d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c RHEUMAZENTRUM RUHRGEBIET   (Germany)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

BIOLOGICAL THERAPY; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE CLASSIFICATION; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; HUMAN; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; SEROLOGY; SPONDYLOARTHROPATHY;

ARTHRITIS, PSORIATIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; SPONDYLARTHROPATHIES;

EID: 14244252091     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.033654     Document Type: Conference Paper

References (38)

1. Moll JM, Haslock I, Macrae IF. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behçet's syndrome. Medicine (Baltimore) 1974;53:343-64.
2. Wright V, Moll JMH, eds. Seronegative polyarthritis. Amsterdam: North Holland Publishing, 1976.
3. Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
4. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
5. Amor D, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies][Article in French]. Rev Rhum Mol Osteoartic 1990;57:85-9.
6. Dougados M, Van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
7. Brandt J, Ballow M, Haberle J, Rudwaleit M, Eggens U, Distler A, et al. The clinical spectrum of patients with inflammatory back pain and peripheral arthritis of the lower limbs: high frequency of undifferentiated spondylarthropathy. Arthritis Rheum 1997;40:S64.
8. Arnett FC. Incomplete Reiter's syndrome: clinical comparisons with classical triad. Ann Rheum Dis 1979;38:73-8.
9. Olivieri I, Cantini F, Salvarani C. Diagnostic and classification criteria, clinical and functional assessment, and therapeutic advances for spondyloarthropathies. Curr Opin Rheumatol 1997;9:284-90.
10. Inman RD. Clinical stratification in the spondylarthropathies: E pluribus unum or ex uno plures? Arthritis Rheum 2001;45:475-7.
11. Collantes E, Veroz R, Escudero A, Munoz E, Munoz MC, Cisnal A, et al. Can some cases of 'possible' spondyloarthropathy be classified as 'definite' or 'undifferentiated' spondyloarthropathy? Value of criteria for spondyloarthropathies. Spanish Spondyloarthropathy Study Group. Joint Bane Spine 2000;67:516-20.
12. Sampaio-Barros PD, Bertolo MB, Kraemer MH, Marques-Neto JF, Samara AM. Undifferentiated spondyloarthropathies: a 2-year follow-up study. Clin Rheumatol 2001;20:201-6.
13. Maugars Y, Berthelot JM, Ducloux JM, Prost A. SAPHO syndrome: a followup study of 19 cases with special emphasis on enthesis involvement. J Rheumatol 1995;22:2135-41.
14. Dougados M, van der Heijde D. Ankylosing spondylitis: how should the disease be assessed? Best Pract Res Clin Rheumatol 2002;16:605-18.
15. Espinoza LR, Cuellar ML. Clinical aspects of the spondyloarthropathies. In: Lopez-Larrea C, eds. HLA-B27 in the development of spondyloarthropathies. Austin: Landes, 1996:1-16.
16. Taurog JD, Hammer RE. Experimental spondylarthropathy in HLA-B-27 transgenic rats. Clin Rheumatol 1996;15:22-7.
17. Prinz JC. Psoriasis vulgaris-a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001;26:326-32.
18. Baeten D, De Keyser F, Mielants H, Veys EM. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2002;16:537-49.
19. McGonagle D, Reade S, Marzo-Ortega H, Gibbon W, O'Connor P, Morgan A, et al. Human immunodeficiency virus associated spondyloarthropathy: pathogenic insights based on imaging findings and response to highly active antiretroviral treatment. Ann Rheum Dis 2001;60:696-8.
20. Sims AM, Wardsworth BP, Brown MA. Genetic susceptibility to ankylosing spondylitis. Curr Mol Med 2004;4:13-20.
21. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990;85:962-3.
22. Kane D, Stafford L, Bresnihan B, FitzGerald O. A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis- "DIP or not DIP revisited". Rheumatology (Oxford) 2003;42:1469-76.
23. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133-8.
24. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in AS. Progress report of the ASAS Working Group. J Rheumatol 1999;26:951-4.
25. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973;1:904-7.
26. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 1982;100:1455-8.
27. Mizuki N, Ota M, Kimura M, Ohno S, Ando H, Katsuyama Y, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet's disease. Proc Natl Acad Sci U S A 1997;94:1298-303.
28. Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M. Psoriasis and HLA-Cw6. Br J Dermatol 1980;102:179-84.
29. Hohhler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, et al. A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997;109:562-5.
30. Gerber LH, Murray CL, Perlman SG, Barth WF, Decker JL, Nigra TA, et al. Human lymphocyte antigens characterizing psoriatic arthritis and its subtypes. J Rheumatol 1982;9:703-7.
31. Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, Sanchez del Rio J, Rodriguez Perez A, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 1999;42:1010-16.
32. Taylor WJ, Harrison AA. Could the Bath Ankylosing Spandylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004;51:311-15.
33. Spoorenberg A, van Tubergen A, Landewé R, et al. Measuring disease activity in Ankylosing Spondylitis (AS). Patient and physician have different perspectives. Rheumatology 2005 (in press).
34. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewe R, Dougados M, Mielants H, et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum 2004;51:154-9.
35. Helliwell PJ, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann Rheum Dis 1998;57:135-40.
36. McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63:162-9.
37. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-6.
38. Braun J, Sieper J. Building consensus an nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002 Ann Rheum Dis 2002;61(suppl 3):iii61-iii67.